Clinical Trial Update: A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the HSP90 inhibitor STA-9090 (ganetespib) in patients with acute myeloid leukemia, acute lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia Blast Phase

Drugs mentioned

• STA-9090 (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED